tiprankstipranks
bioAffinity Technologies, Inc. (BIAF)
NASDAQ:BIAF
US Market

bioAffinity Technologies, Inc. (BIAF) Stock Price & Analysis

16 Followers

BIAF Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.95 - $3.62
Previous Close$2.09
Volume49.79K
Average Volume (3M)171.90K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$4.50M
Total Debt (Recent Filing)$1.69M
Price to Earnings (P/E)-2.5
Beta2.37
Mar 29, 2024
Next Dividend Ex-DateN/A
Expense RatioN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding9,502,243
10 Day Avg. Volume213,719
30 Day Avg. Volume171,903
Standard Deviation0.27
R-Squared0.44
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)4.05
Price to Sales (P/S)4194.20
Price to Cash Flow (P/CF)-3.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

37.21%0.26%0.91%61.63%
37.21% Insiders
0.91% Other Institutional Investors
61.63% Public Companies and
Individual Investors

BIAF FAQ

What was bioAffinity Technologies, Inc.’s price range in the past 12 months?
bioAffinity Technologies, Inc. lowest stock price was $0.95 and its highest was $3.62 in the past 12 months.
    What is bioAffinity Technologies, Inc.’s market cap?
    Currently, no data Available
    When is bioAffinity Technologies, Inc.’s upcoming earnings report date?
    bioAffinity Technologies, Inc.’s upcoming earnings report date is Mar 29, 2024 which is tomorrow.
      How were bioAffinity Technologies, Inc.’s earnings last quarter?
      bioAffinity Technologies, Inc. released its earnings results on Nov 14, 2023. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.18 by -$0.08.
        Is bioAffinity Technologies, Inc. overvalued?
        According to Wall Street analysts bioAffinity Technologies, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does bioAffinity Technologies, Inc. pay dividends?
          bioAffinity Technologies, Inc. does not currently pay dividends.
          What is bioAffinity Technologies, Inc.’s EPS estimate?
          bioAffinity Technologies, Inc.’s EPS estimate is -$0.2.
            How many shares outstanding does bioAffinity Technologies, Inc. have?
            bioAffinity Technologies, Inc. has 11,449,506 shares outstanding.
              What happened to bioAffinity Technologies, Inc.’s price movement after its last earnings report?
              bioAffinity Technologies, Inc. reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.18. Following the earnings report the stock price went down -1.389%.
                Which hedge fund is a major shareholder of bioAffinity Technologies, Inc.?
                Currently, no hedge funds are holding shares in BIAF
                ---

                bioAffinity Technologies, Inc. Stock Smart Score

                N/A
                Not Ranked
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Technicals

                SMA
                Positive
                20 days / 200 days
                Momentum
                14.20%
                12-Months-Change

                Fundamentals

                Return on Equity
                -73.89%
                Trailing 12-Months
                Asset Growth
                -27.54%
                Trailing 12-Months

                Company Description

                bioAffinity Technologies, Inc.

                bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company is involved in developing technologies that, in the future, will be able to detect and monitor diseases of the lung and other cancers and treat many cancers.
                ---
                Similar Stocks
                Company
                Price & Change
                Follow
                BioNano Genomics
                Onconova Therapeutics
                Advaxis
                CytoDyn
                Popular Stocks
                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis